BEGIN:VCALENDAR
VERSION:2.0
PRODID:-// - ECPv4.7.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.mdtechcouncil.com/membership/events
X-WR-CALDESC:Events for 
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20210928T110000
DTEND;TZID=America/New_York:20210928T120000
DTSTAMP:20260417T184912
CREATED:20210923T191208Z
LAST-MODIFIED:20210923T191208Z
UID:2325-1632826800-1632830400@www.mdtechcouncil.com
SUMMARY:NCI Tech Opportunity Webinar: Single Domain Antibodies Targeting SARS-CoV-2 for treating COVID-19
DESCRIPTION:Register here .\nAttendees will hear from the NCI’s Dr. Mitchell Ho  about a potential therapeutic treatment for COVID-19\, “Single Domain Antibodies Targeting SARS-CoV2 for Treating Covid-19.”  There are few therapeutics available for COVID-19 patients that directly target the SARS-CoV-2 novel coronavirus. COVID-19 is caused by SARS-CoV-2\, which infects hosts via its spike (S) protein. The S protein contains a receptor binding domain (RBD) that binds to an angiotensin converting enzyme 2 (ACE2) receptor on human cells to facilitate viral entry and infection. Dr. Ho’s lab isolated three lead nanobodies\, 7A3\, 1B5\, and 2F7\, which were found to be highly effective at blocking RBD-ACE2 binding interactions. This nanobody panel has the potential to block the binding of the S-protein to the ACE2 receptor\, thereby preventing SARS-CoV-2 virus from binding to and entering a host cells to cause COVID-19 infection. \nWhy attend?\n\nAssess co-developing and/or licensing this technology\nInteract with the inventor\, ask questions and provide feedback\nLearn the advantages of partnering with the NCI\n\nWho should attend?\n\nBusiness development professionals\nDrug development professionals\nBiotech/pharma/academic researchers\nInvestors and entrepreneurs\n\nAbout the featured technology\nThis technology is pre-clinical with identified lead compounds. It is patent pending and available for licensing or co-development. \n
URL:https://www.mdtechcouncil.com/membership/events/calendar/nci-tech-opportunity-webinar-single-domain-antibodies-targeting-sars-cov-2-for-treating-covid-19/
LOCATION:Virtual\, United States
GEO:37.09024;-95.712891
CATEGORIES:Life Science
END:VEVENT
END:VCALENDAR